Immuneering Corp [IMRX] stock is trading at $2.39, down -2.45%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The IMRX shares have gain 3.02% over the last week, with a monthly amount glided 106.03%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Immuneering Corp [NASDAQ: IMRX] stock has seen the most recent analyst activity on March 15, 2024, when Needham reiterated its Buy rating and also revised its price target to $15 from $20. Previously, TD Cowen downgraded its rating to Market Perform on March 15, 2024. On March 15, 2024, downgrade downgraded it’s rating to Hold and revised its price target to $3 on the stock. Needham started tracking the stock assigning a Buy rating and suggested a price target of $20 on December 01, 2023. Morgan Stanley upgraded its rating to Equal-Weight for this stock on April 19, 2023, and upped its price target to $14. In a note dated April 19, 2023, Mizuho upgraded an Buy rating on this stock and boosted its target price from $10 to $20.
Immuneering Corp [IMRX] stock has fluctuated between $1.00 and $8.89 over the past year. Currently, Wall Street analysts expect the stock to reach $17.5 within the next 12 months. Immuneering Corp [NASDAQ: IMRX] shares were valued at $2.39 at the most recent close of the market. An investor can expect a potential return of 632.22% based on the average IMRX price forecast.
Analyzing the IMRX fundamentals
Gross Profit Margin for this corporation currently stands at 1.01% with Operating Profit Margin at 0.64%, Pretax Profit Margin comes in at 0.59%, and Net Profit Margin reading is 0.59%. To continue investigating profitability, this company’s Return on Assets is posted at -0.73, Equity is -0.66 and Total Capital is -0.86. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.28 points at the first support level, and at 2.16 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.53, and for the 2nd resistance point, it is at 2.66.
Ratios To Look Out For
For context, Immuneering Corp’s Current Ratio is 9.39. As well, the Quick Ratio is 9.39, while the Cash Ratio is 8.81.
Transactions by insiders
Recent insider trading involved Cormorant Asset Management, LP, 10% Owner, that happened on Apr 01 ’24 when 0.4 million shares were sold. Director, Schall Thomas J. completed a deal on Mar 22 ’24 to buy 2900.0 shares. Meanwhile, Director Feinberg Peter bought 25000.0 shares on Mar 22 ’24.
